Microcap Ledger Pulmonx Corp $LUNG
Facts as of . Built from SEC filings and our own data. Small caps move fast; check the latest filings.
Snapshot
- Exchange
- Nasdaq Global Select Market
- Sector
- Surgical & Medical Instruments & Apparatus
- Headquarters
- Redwood City, CA
- Fiscal year end
- December 31
- Shares outstanding
- 42,948,269 [10-Q 2026-08-04]
What the company doesAI summary of filing
Pulmonx Corporation is a commercial-stage medical technology company that develops and sells minimally invasive treatments for patients with severe emphysema, a form of chronic obstructive pulmonary disease. The company's primary product is the Zephyr Endobronchial Valve, which received FDA pre-market approval in 2018 and is now commercially available in numerous countries. Pulmonx generates revenue by selling Zephyr Valves and related delivery systems to hospitals, along with smaller amounts from its Chartis Pulmonary Assessment System and LungTraX Platform cloud-based CT analysis service. In 2025, the company generated $90.5 million in revenue with a gross margin of 74.2%, though it reported a net loss of $54.0 million and has an accumulated deficit of $521.6 million. [10-K 2026-03-10]
Financial health
| Period | Revenue | Net income | Operating cash flow | Cash | Filing |
|---|---|---|---|---|---|
| 6 months to Jun 2026 | $43.34M | −$23.73M | −$15.31M | $55.84M | [10-Q 2026-08-04] |
| FY ended Dec 2025 | $90.50M | −$54.00M | −$32.38M | $69.75M | [10-K 2026-03-10] |
| FY ended Dec 2024 | $83.79M | −$56.39M | −$31.54M | $70.91M | [10-K 2026-03-10] |
- Quarterly cash burn
- −$7.66M
- Cash runway Estimate
- ~21.9 months
Capital structure and dilution
| Date | Shares outstanding | Filing |
|---|---|---|
| 2024-10-28 | 39,487,879 | [10-Q 2024-11-01] |
| 2025-02-14 | 39,796,420 | [10-K 2025-02-25] |
| 2025-04-25 | 40,257,527 | [10-Q 2025-05-02] |
| 2025-07-25 | 40,746,556 | [10-Q 2025-08-01] |
| 2025-10-31 | 41,247,034 | [10-Q 2025-11-12] |
| 2026-03-03 | 42,237,203 | [10-K 2026-03-10] |
| 2026-04-27 | 42,237,203 | [10-Q 2026-05-04] |
| 2026-07-31 | 42,948,269 | [10-Q 2026-08-04] |
- Shelf registration
- S-3 filed 2025-09-26; declared effective 2025-11-25 [S-3 2025-09-26]
Listing status
Current status: No Form 8-K Item 3.01 (listing notice) filings in the last 24 months, as of 2026-10-11.
Who owns it
| Date | Insider | Type | Shares | Price | Filing |
|---|---|---|---|---|---|
| 2026-09-01 | French Glendon E. Iii | sell | 4,098 | $2.26 | [4 2026-09-03] |
| 2026-09-01 | French Glendon E. Iii | sell | 37,784 | $2.26 | [4 2026-09-03] |
| 2026-09-01 | Radhakrishnan Srikanth | sell | 2,643 | $2.26 | [4 2026-09-03] |
| 2026-09-01 | Radhakrishnan Srikanth | sell | 2,121 | $2.26 | [4 2026-09-03] |
| 2026-09-01 | Radhakrishnan Srikanth | sell | 3,618 | $2.26 | [4 2026-09-03] |
| 2026-09-01 | Radhakrishnan Srikanth | sell | 5,863 | $2.26 | [4 2026-09-03] |
| 2026-09-01 | Lehman David Aaron | sell | 3,807 | $2.26 | [4 2026-09-03] |
| 2026-09-01 | Lehman David Aaron | sell | 2,224 | $2.26 | [4 2026-09-03] |
| 2026-09-01 | Lehman David Aaron | sell | 3,476 | $2.26 | [4 2026-09-03] |
| 2026-09-01 | Lehman David Aaron | sell | 4,827 | $2.26 | [4 2026-09-03] |
| 2026-09-01 | Rose Geoffrey Beran | sell | 2,213 | $2.26 | [4 2026-09-03] |
| 2026-09-01 | Rose Geoffrey Beran | sell | 2,390 | $2.26 | [4 2026-09-03] |
Catalysts and calendar
| Date | Type | Title |
|---|---|---|
| 2026-08-13 | 13G/A | Beneficial ownership report (5%+ holder) |
| 2026-08-04 | 10-Q | Quarterly report |
| 2026-07-29 | 8-K | Results of operations |
| 2026-07-29 | 13G/A | Beneficial ownership report (5%+ holder) |
| 2026-06-04 | 8-K | Shareholder vote results |
| 2026-05-04 | 10-Q | Quarterly report |
| 2026-04-29 | 8-K | Results of operations |
| 2026-04-22 | DEF 14A | Proxy statement |
| 2026-03-27 | 13G/A | Beneficial ownership report (5%+ holder) |
| 2026-03-10 | 10-K | Annual report |
| 2026-03-09 | 13G | Beneficial ownership report (5%+ holder) |
| 2026-03-05 | 8-K | Material agreement entered; Material agreement terminated; New financial obligation |
Alerts for $LUNG
Email me when Pulmonx Corp files an offering, gets a deficiency notice, or moves sharply.
Facts as of . Small caps move fast; check the latest filings.